Get started
Author

Ann‐Marie Tindberg

Observed names: Ann-Marie Tindberg, Tindberg, Ann-Marie
ORCID: 0000-0001-7185-7472
Observed ORCID: 0000-0001-7185-7472
OpenAlex ID: A5090424490
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
2022 · Jonathan I. Silverberg, David N. Adam, et al. · American Journal of Clinical Dermatology · 57
PDF
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
2023 · Eric L. Simpson, Andrew E. Pink, et al. · American Journal of Clinical Dermatology · 37
PDF
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
2024 · Stephan Weidinger, Anthony Bewley, et al. · British Journal of Dermatology · 18
PDF
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
2025 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 9
PDF
551 - Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control
2024 · Andrew Blauvelt, Richard G Langley, et al. · British Journal of Dermatology · 6
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
2026 · Andrew Blauvelt, H. Chih-Ho Hong, et al. · Dermatology and Therapy · 5
PDF
Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
2025 · Melinda Gooderham, Mahreen Ameen, et al. · Journal of the European Academy of Dermatology and Venereology · 5
PDF
Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years
2025 · Andrew Blauvelt, Vivian Laquer, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
2024 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 3
Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials
2024 · Kristian Reich, Richard G. Langley, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
650 - Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
2024 · Andrew Blauvelt, H Chih-ho Hong, et al. · British Journal of Dermatology · 2
Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial
2026 · Benjamin Ehst, Richard B Warren, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
53133 Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
2024 · Andrew Blauvelt, Chi-ho Hong, et al. · Journal of the American Academy of Dermatology · 1
PDF
Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis
2024 · Andrew Blauvelt, Chih-ho Hong, et al. · SKIN The Journal of Cutaneous Medicine · 1
555 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
2024 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 1
Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD
2026 · April Armstrong, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Tralokinumab Significantly Reduces Work Productivity Impairment and Daily Activity Impairment in Adults With Atopic Dermatitis and Moderate-to-Severe Hand Involvement
2026 · Benjamin Ehst, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Long-term safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis treated for up to 6 years: Final results from the open-label extension trial ECZTEND
2026 · Adis Journals on behalf of:, Blauvelt, Andrew, et al. · Figshare
651 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · British Journal of Dermatology
Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control
2024 · Andrew Blauvelt, Richard G. Langley, et al. · SKIN The Journal of Cutaneous Medicine
PDF
552 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · British Journal of Dermatology
Improvement of the Head and Neck Regions with Continuous Tralokinumab treatment for Up to 4 years in Adults with Moderate-to-Severe Atopic Dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · SKIN The Journal of Cutaneous Medicine
PDF
324 Tralokinumab provides progressive and sustained efficacy in adolescents with moderate-to-severe atopic dermatitis: a post-hoc analysis of the ECZTRA 6 trial
2023 · Eric L Simpson, Andreas Wollenberg, et al. · British Journal of Dermatology
Works count: 23
Citation count: 152
H-index: 5
I10-index: 3
Year
Topic
Type